| Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
| Tel: |
400-9205774 400-920-5774 |
| Email: |
sales@glpbio.cn |
| Products Intro: |
Product Name:8-iso-13,14-dihydro-15-keto Prostaglandin F2α CAS:191919-02-5 Purity:>98% Package:1mg;10mg;50mg;100mg;
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:8-iso-13,14-dihydro-15-keto Prostaglandin F2α CAS:191919-02-5 Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:8-iso-13,14-dihydro-15-keto Prostaglandin F2α CAS:191919-02-5 Purity:98% Package:50μg;100μg;500μg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:8-iso-13,14-dihydro-15-keto Prostaglandin F2α CAS:191919-02-5 Package:1mg/RMB 25900
|
(Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid manufacturers
|
| | (Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid Basic information |
| Product Name: | (Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid | | Synonyms: | 8-iso-13,14-dihydro-15-keto-PGF2a;8-iso-13,14-dihydro-15-keto Prostaglandin F2α;VKTIONYPMSCHQI-JPRPWBOBSA-N;(Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid;Prost-5-en-1-oic acid, 9,11-dihydroxy-15-oxo-, (5Z,8β,9α,11α)- | | CAS: | 191919-02-5 | | MF: | C20H34O5 | | MW: | 354.48 | | EINECS: | | | Product Categories: | | | Mol File: | 191919-02-5.mol | ![(Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid Structure](CAS/GIF/191919-02-5.gif) |
| | (Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid Chemical Properties |
| Boiling point | 543.0±40.0 °C(Predicted) | | density | 1.091±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | 10 mM Na2CO3: >6.5 mg/ml; DMF: >100 mg/ml; DMSO: >100 mg/ml; Ethanol: >100 mg/ml; PBS (pH 7.2): >10 mg/ml | | pka | 4.76±0.10(Predicted) |
| | (Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid Usage And Synthesis |
| Description | 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite of the isoprostane, 8-isoprostane (8-iso PGF2α), in rabbits, monkeys and humans.1 8-iso PGF2α is a PG-like product of non-specific lipid peroxidation.2 In both humans and monkeys, exogenously infused 8-isoprostane is converted primarily to metabolites having 2 or 4 carbon atoms removed from the top side chain by β-oxidation.1 A similar pattern is observed when tritiated 8-isoprostane is infused into rabbits.3 Early in the infusion (within 10 minutes) 8-iso-13,14-dihydro-15-keto PGF2α was a significant component of the metabolite profile, which was comprised mostly of dinor 8-isoprostane metabolites. 8-iso-13,14-dihydro-15-keto PGF2α weakly inhibits the U-46619 or collagen-induced aggregation of human platelets, although a number of the E-series isoprostanes are much more potent in this assay.4 | | Uses | 8-iso-13,14-dihydro-15-keto Prostaglandin F2α is an oxidative metabolite of 8-iso-prostaglandin F2α (HY-113209). 8-iso-13,14-dihydro-15-keto Prostaglandin F2α can be used in the study of oxidative stress-related diseases[1]. | | References | 1. Chiabrando, C., Valagussa, A., Rivalta, C., et al. Identification and measurement of endogenous β-oxidation metabolites of 8-epi-prostaglandin F2α J. Biol. Chem. 274(3),1313-1319(1999). 2. Morrow, J.D., Hill, K.E., Burk, R.F., et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl. Acad. Sci. USA 87(23),9383-9387(1990). 3. Basu, S. Metabolism of 8-iso-prostaglandin F2α FEBS Lett. 428(112),32-36(1998). 4. Cranshaw, J.H., Evans, T.W., and Mitchell, J.A. Charcterization of the effects of isoprostanes on platelet aggregation in human whole blood Br. J. Pharmacol. 132,1699-1706(2001). |
| | (Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid Preparation Products And Raw materials |
|